CN110325515B - 作为ⅲ型受体酪氨酸激酶抑制剂的喹喔啉化合物 - Google Patents

作为ⅲ型受体酪氨酸激酶抑制剂的喹喔啉化合物 Download PDF

Info

Publication number
CN110325515B
CN110325515B CN201780075303.1A CN201780075303A CN110325515B CN 110325515 B CN110325515 B CN 110325515B CN 201780075303 A CN201780075303 A CN 201780075303A CN 110325515 B CN110325515 B CN 110325515B
Authority
CN
China
Prior art keywords
methoxy
carbonitrile
amino
morpholinoquinoxaline
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780075303.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110325515A (zh
Inventor
彭劭政
廖助彬
陈泓恺
何承璇
黄鸿钧
邱显益
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Publication of CN110325515A publication Critical patent/CN110325515A/zh
Application granted granted Critical
Publication of CN110325515B publication Critical patent/CN110325515B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780075303.1A 2016-10-10 2017-10-09 作为ⅲ型受体酪氨酸激酶抑制剂的喹喔啉化合物 Active CN110325515B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406328P 2016-10-10 2016-10-10
US62/406,328 2016-10-10
PCT/US2017/055809 WO2018071348A1 (en) 2016-10-10 2017-10-09 Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
CN110325515A CN110325515A (zh) 2019-10-11
CN110325515B true CN110325515B (zh) 2023-06-20

Family

ID=61905910

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075303.1A Active CN110325515B (zh) 2016-10-10 2017-10-09 作为ⅲ型受体酪氨酸激酶抑制剂的喹喔啉化合物

Country Status (13)

Country Link
US (1) US10689362B2 (enExample)
EP (1) EP3523285A4 (enExample)
JP (1) JP7206188B2 (enExample)
KR (1) KR102609813B1 (enExample)
CN (1) CN110325515B (enExample)
AU (1) AU2017342928B2 (enExample)
BR (1) BR112019007271A2 (enExample)
CA (1) CA3039919A1 (enExample)
IL (1) IL265829B (enExample)
RU (1) RU2019113764A (enExample)
SG (1) SG11201903091VA (enExample)
TW (1) TWI648266B (enExample)
WO (1) WO2018071348A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195511A1 (en) * 2020-09-21 2022-03-24 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
CN117545507A (zh) * 2021-04-26 2024-02-09 小利兰·斯坦福大学托管委员会 生化激活功能障碍骨骼干细胞以实现骨骼再生
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN115141177B (zh) * 2022-08-30 2022-12-09 福贝生物科技(苏州)有限公司 喹喔啉类化合物马来酸盐的新晶型及其制备方法
WO2025019622A2 (en) * 2023-07-18 2025-01-23 Elixiron Immunotherapeutics Inc. Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors
WO2025067450A1 (zh) * 2023-09-28 2025-04-03 福贝生物医药科技(北京)有限公司 一种固体分散体、药物组合物、其制备方法及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
CN1842522A (zh) * 2003-06-25 2006-10-04 科学研究和应用咨询公司 在5或6位具有取代基的苯并噻唑－4,7－二酮与苯并噁唑－4,7－二酮和它们的制备方法
US7304092B1 (en) * 2002-11-12 2007-12-04 Yale University Compounds and methods for treating tumors, cancer and hyperproliferative diseases
CN101166726A (zh) * 2005-05-05 2008-04-23 色品疗法有限公司 作为激酶酶活性抑制剂的喹啉和喹喔啉衍生物
CN101432281A (zh) * 2006-04-19 2009-05-13 诺瓦提斯公司 6-o-取代的苯并唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
CN102036963A (zh) * 2008-05-23 2011-04-27 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
WO2013112950A2 (en) * 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104024233A (zh) * 2011-10-28 2014-09-03 阿斯特克斯治疗有限公司 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2010528T3 (pl) * 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA2772790C (en) * 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
KR20160125527A (ko) * 2012-04-17 2016-10-31 후지필름 가부시키가이샤 함질소 복소환 화합물 또는 그 염
WO2014075077A1 (en) * 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10517844B2 (en) * 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860433A1 (en) * 1995-11-07 1998-08-26 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US7304092B1 (en) * 2002-11-12 2007-12-04 Yale University Compounds and methods for treating tumors, cancer and hyperproliferative diseases
CN1842522A (zh) * 2003-06-25 2006-10-04 科学研究和应用咨询公司 在5或6位具有取代基的苯并噻唑－4,7－二酮与苯并噁唑－4,7－二酮和它们的制备方法
CN101166726A (zh) * 2005-05-05 2008-04-23 色品疗法有限公司 作为激酶酶活性抑制剂的喹啉和喹喔啉衍生物
CN101432281A (zh) * 2006-04-19 2009-05-13 诺瓦提斯公司 6-o-取代的苯并唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
CN102036963A (zh) * 2008-05-23 2011-04-27 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
CN104024233A (zh) * 2011-10-28 2014-09-03 阿斯特克斯治疗有限公司 通过fgfr激酶的抑制抗癌的苯并吡嗪类化合物
WO2013112950A2 (en) * 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods

Also Published As

Publication number Publication date
IL265829B (en) 2022-06-01
AU2017342928B2 (en) 2021-09-09
SG11201903091VA (en) 2019-05-30
EP3523285A4 (en) 2020-04-22
BR112019007271A2 (pt) 2019-09-17
AU2017342928A1 (en) 2019-05-23
TW201817720A (zh) 2018-05-16
KR20190059959A (ko) 2019-05-31
CA3039919A1 (en) 2018-04-19
TWI648266B (zh) 2019-01-21
EP3523285A1 (en) 2019-08-14
RU2019113764A3 (enExample) 2021-01-29
KR102609813B1 (ko) 2023-12-07
IL265829A (en) 2019-06-30
JP7206188B2 (ja) 2023-01-17
RU2019113764A (ru) 2020-11-13
CN110325515A (zh) 2019-10-11
US10689362B2 (en) 2020-06-23
WO2018071348A1 (en) 2018-04-19
US20190308949A1 (en) 2019-10-10
JP2019530708A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
CN110325515B (zh) 作为ⅲ型受体酪氨酸激酶抑制剂的喹喔啉化合物
KR101211950B1 (ko) Ｐａｒｐ 저해제로서의 프탈아진 유도체
KR101286969B1 (ko) Ｐａｒｐ 저해제로서의 퀴나졸리논 유도체
AU2012299899B2 (en) Bicyclic heteroaromatic compounds
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
MXPA06004194A (es) Inhibicion de fgfr3 y tratamiento de mieloma multiple.
TW200413349A (en) Benzimidazole quinolinones and uses thereof
WO2014040549A1 (zh) 炔杂芳环化合物及其应用
KR20160104003A (ko) 세린/트레오닌 키나아제 억제제
AU2012204651A1 (en) Novel bicyclic compound or salt thereof
WO2025034951A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
AU2016341259B2 (en) Pyridone derivatives and their use as kinase inhibitors
CN1976706B (zh) 抑制fgfr3及治疗多发性骨髓瘤
HK40012508B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
HK40012508A (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012508

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant